Abstract WP285: tPA Variant tPA-A296-299 Prevents Impairment of Cerebral Autoregulation and Hippocampal Neuronal Necrosis After Stroke Through Inhibition of ET-1 Upregulation

William M. Armstead,Hugh Hekierski,Serge Yarovoi,Abd Al-Roof Higazi,Douglas B. Cines

Abstract WP285: tPA Variant tPA-A296-299 Prevents Impairment of Cerebral Autoregulation and Hippocampal Neuronal Necrosis After Stroke Through Inhibition of ET-1 Upregulation

2017

William M. Armstead
Hugh Hekierski
Serge Yarovoi
Abd Al-Roof Higazi
Douglas B. Cines

Introduction: The sole FDA approved treatment for acute stroke is tissue type plasminogen activator (tPA). However, its brief therapeutic window and post-treatment complications markedly constrain ...

Keywords:

Neuroprotection
Cerebral autoregulation
Physical therapy
Diabetes mellitus
Pharmacology
Necrosis
Hippocampal formation
Plasminogen activator
Stroke
Medicine
Downregulation and upregulation
neuronal necrosis

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations